Developer docs
API playgroundTry for free, no card

Search company profiles

Abionyx Pharma

Full company profile

uuid0004p8a

Namestring
Abionyx Pharma
Legal namestring
ABIONYX Pharma SA
Websiteurl
abionyx.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

ABIONYX Pharma SA is a French publicly-traded biotech (Euronext Paris: ABNX) developing HDL-based biomedicines for indications with no approved therapy, including LCAT deficiency (a rare renal disease), sepsis, and ophthalmological conditions. Its core product is CER-001, a recombinant apoA-I HDL vector biomedicine, manufactured using a proprietary platform that combines high-performance apoA-I bioproduction with exclusive mastery of ultra-pure synthetic sphingomyelin. A March 2026 breakthrough delivered a threefold increase in sphingomyelin production yield. A second pipeline asset, ABNX-100, is referenced as an additional therapeutic candidate. The company is pursuing an EMA Marketing Authorization Application for CER-001 in LCAT deficiency targeted for early 2028, alongside a Phase 2b sepsis trial, and holds published clinical evidence from the RACERS study in BMC Medicine/Nature Springer.

The company's revenue model is bifurcated. All current consolidated revenue — EUR 4.1M in FY2025 and EUR 0.83M in Q1 2026 — is generated entirely by its wholly-owned IRIS Pharma subsidiary, a contract research organization specializing in ophthalmology that serves external pharmaceutical and biotech clients through direct enterprise engagements. The therapeutic development business (CER-001, ABNX-100) is pre-commercial and contributes zero revenue. Non-dilutive government funding (EUR 8.7M France 2030 i-Démo, ~EUR 1M Bpifrance) supplements the funding mix alongside equity (EUR 18.7M rights issue in June 2026) and non-convertible bond financing (up to EUR 14M from Fenja Capital II A/S), extending the cash runway into Q4 2028.

Go-to-market is enterprise and regulatory: the company targets institutional healthcare stakeholders, the EMA regulatory pathway, and strategic partners (e.g., SEBIA for companion diagnostics in sepsis). Distribution is pre-commercial for therapeutics and direct enterprise sales for IRIS Pharma CRO services. The company operates from Balma, France, with a headcount of 1–10 employees, and is led by CEO Cyrille Tupin, CMO Rob Scott, and CDIO Laurent Guerci.

Short descriptiontext

ABIONYX Pharma SA is a French pre-commercial biotech developing HDL-based biomedicines (CER-001, ABNX-100) for LCAT deficiency, sepsis, and ophthalmology, with all current revenue generated by its IRIS Pharma ophthalmology CRO subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBalma, France
HQ citystring
Balma
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical drug development, HDL vector drug delivery, rare disease therapeutics, clinical stage biotech, ophthalmology contract research
Industry2 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services (IRIS Pharma)
TypeProfessional Services
Description

Revenue is generated entirely through IRIS Pharma, a contract research organization (CRO) specializing in ophthalmology. The therapeutic development business (CER-001, ABNX-100) generates no revenue as products remain in clinical development.

morningstar.com
2Non-dilutive Government Funding
TypeLicensing Royalties
Description

The company secures non-dilutive funding through grants and programs such as France 2030's i-Démo program (€8.7 million secured, €6.5 million remaining) and Bpifrance innovation grants (nearly €1 million for CER-001 ophthalmology development).

businesswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ABIONYX Pharma is a clinical-stage biotech developing HDL-based biomedicines, principally lead candidate CER-001 (a recombinant apoA-I biomedicine) for LCAT deficiency, sepsis, and ophthalmological indications, along with ABNX-100 as a second pipeline candidate. The company complements its therapeutic development business with its wholly-owned IRIS Pharma subsidiary, a contract research organization that delivers ophthalmology research services and currently generates all of the group's consolidated revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Threefold increase in sphingomyelin production yield for CER-001 manufacturing
+2 more records
Product overview1 text field

ABIONYX Pharma is a new-generation biotech company developing innovative therapies through two main drug candidates: CER-001 (a HDL-based biomedicine for LCAT deficiency, sepsis, and ophthalmology) and ABNX-100. The company also operates through its IRIS Pharma subsidiary, a contract research organization providing ophthalmology research services. The product portfolio centers on HDL vectors used for targeted drug delivery in renal, ophthalmological, and rare diseases where no effective treatment exists.

Product and service3 records
1CER-001
CategoryTherapeutic drug candidate (biomedicine)
Description

CER-001 is ABIONYX Pharma's lead biomedicine drug candidate, based on a recombinant apoA-I HDL vector technology, being developed for the treatment of LCAT (Lecithin-Cholesterol Acyltransferase) deficiency, sepsis, and ophthalmological indications. It is targeted at patients with rare and unmet medical needs, and is being progressed toward a Marketing Authorization Application with the EMA targeted for early 2028.

2ABNX-100
CategoryTherapeutic drug candidate (pipeline)
Description

ABNX-100 is a pipeline drug candidate of ABIONYX Pharma, referenced alongside CER-001 as one of the company's key therapeutic assets for innovative applications leveraging the company's HDL-based bioproduct platform.

3IRIS Pharma CRO services
CategoryContract research services (ophthalmology)
Description

IRIS Pharma is the wholly-owned contract research organization (CRO) subsidiary of ABIONYX Pharma, specializing in ophthalmology research services for pharmaceutical and biotech companies. It generated all of ABIONYX's consolidated revenue (€4.1 million in FY2025) and had €2.6 million in business secured for FY2026.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-20
Description

ABIONYX Pharma and SEBIA announced an exclusive global strategic partnership focused on developing new diagnostic tests for early detection and monitoring of sepsis. The partnership aims to improve sepsis management through combined expertise in lipid biology, clinical studies, and blood sample analysis.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Esperion commercializes bempedoic acid (Nexletol/Nexlizet) for LDL cholesterol lowering, addressing lipid-related cardiovascular disease with a similar therapeutic-area focus to ABIONYX. As a small-cap public commercial-stage peer, it offers a comparable go-to-market benchmark for lipid-targeting therapeutics.

TypeDirect peer
Description

Ionis is a leader in antisense oligonucleotide therapies for serious and rare diseases, with multiple approved products (e.g., Waylivra, Tegsedi). Its rare-disease platform focus, lipid targets, and Phase 2-3 pipeline profile closely parallel ABIONYX's specialty biotech model targeting LCAT deficiency and rare renal/ophthalmology indications.

TypeEmerging player
Description

Arrowhead develops RNAi-based therapies for rare diseases, leveraging a targeted-delivery platform. Its platform-based approach to delivering therapeutics to specific tissues parallels ABIONYX's HDL vector delivery concept, making it a useful comparator for technology-driven rare-disease biotechs.

TypeEmerging player
Description

Madrigal developed Rezdiffra, the first FDA-approved therapy for MASH/NASH, addressing a rare metabolic liver disease with no prior approved options. Comparable as a specialty biotech that achieved commercial approval in a previously untreated rare metabolic indication, similar to ABIONYX's LCAT deficiency strategy.

TypeEmerging player
Description

Travere develops therapies for rare kidney diseases (e.g., Filspari for IgA nephropathy), making it a direct comparable to ABIONYX's LCAT deficiency renal focus. It provides a benchmark for small-cap rare renal disease biotechs progressing from clinical to commercial stages.

TypeBroad incumbent
Description

Recordati's rare diseases division commercializes treatments for rare metabolic and endocrine disorders globally. As an established rare-disease commercial player, it offers a comparable commercialization model and potential partner for CER-001 in LCAT deficiency upon EMA approval.

TypeEmerging player
Description

CymaBay developed seladelpar (Livdelzi) for primary biliary cholangitis, a rare autoimmune liver disease. Similar to ABIONYX, it is a small public clinical-to-commercial biotech that targeted a rare disease with no effective existing treatment.

TypeBroad incumbent
Description

CSL Behring developed CSL112, an apoA-I infusion therapy very similar in mechanism to CER-001, for cardiovascular indications. It is a major plasma-derived therapeutics incumbent with global commercialization infrastructure, providing both a technology comparable and a precedent (the AEGIS-II Phase 3 outcome) for ABIONYX's HDL-mimetic approach.

TypeBroad incumbent
Description

Sobi is a Swedish specialty biopharma focused on rare diseases, with a portfolio spanning hematology, immunology, and specialty therapeutics. It represents a potential commercialization partner or acquisition counterparty for ABIONYX's rare-disease pipeline, particularly for European orphan drug launches.

TypeEmerging player
Description

Akari is a clinical-stage biotech developing therapies for rare autoimmune and inflammatory diseases, including nomacopan for conditions with high unmet need. Comparable to ABIONYX as a small-cap public rare-disease biotech with limited headcount and a single-platform therapeutic pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abionyx Pharma

Biopharmaceuticalsabionyx.com

ABIONYX Pharma SA is a French pre-commercial biotech developing HDL-based biomedicines (CER-001, ABNX-100) for LCAT deficiency, sepsis, and ophthalmology, with all current revenue generated by its IRIS Pharma ophthalmology CRO subsidiary.

What Abionyx Pharma does

ABIONYX Pharma SA is a French publicly-traded biotech (Euronext Paris: ABNX) developing HDL-based biomedicines for indications with no approved therapy, including LCAT deficiency (a rare renal disease), sepsis, and ophthalmological conditions. Its core product is CER-001, a recombinant apoA-I HDL vector biomedicine, manufactured using a proprietary platform that combines high-performance apoA-I bioproduction with exclusive mastery of ultra-pure synthetic sphingomyelin. A March 2026 breakthrough delivered a threefold increase in sphingomyelin production yield. A second pipeline asset, ABNX-100, is referenced as an additional therapeutic candidate. The company is pursuing an EMA Marketing Authorization Application for CER-001 in LCAT deficiency targeted for early 2028, alongside a Phase 2b sepsis trial, and holds published clinical evidence from the RACERS study in BMC Medicine/Nature Springer.

The company's revenue model is bifurcated. All current consolidated revenue — EUR 4.1M in FY2025 and EUR 0.83M in Q1 2026 — is generated entirely by its wholly-owned IRIS Pharma subsidiary, a contract research organization specializing in ophthalmology that serves external pharmaceutical and biotech clients through direct enterprise engagements. The therapeutic development business (CER-001, ABNX-100) is pre-commercial and contributes zero revenue. Non-dilutive government funding (EUR 8.7M France 2030 i-Démo, ~EUR 1M Bpifrance) supplements the funding mix alongside equity (EUR 18.7M rights issue in June 2026) and non-convertible bond financing (up to EUR 14M from Fenja Capital II A/S), extending the cash runway into Q4 2028.

Go-to-market is enterprise and regulatory: the company targets institutional healthcare stakeholders, the EMA regulatory pathway, and strategic partners (e.g., SEBIA for companion diagnostics in sepsis). Distribution is pre-commercial for therapeutics and direct enterprise sales for IRIS Pharma CRO services. The company operates from Balma, France, with a headcount of 1–10 employees, and is led by CEO Cyrille Tupin, CMO Rob Scott, and CDIO Laurent Guerci.

Abionyx Pharma firmographics

Firmographics
Name
Abionyx Pharma
Legal name
ABIONYX Pharma SA
Website
https://abionyx.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
ABIONYX Pharma SA is a French pre-commercial biotech developing HDL-based biomedicines (CER-001, ABNX-100) for LCAT deficiency, sepsis, and ophthalmology, with all current revenue generated by its IRIS Pharma ophthalmology CRO subsidiary.
Ownership category
akta.pro rank

Abionyx Pharma industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Biopharmaceutical drug development
  • HDL vector drug delivery
  • Rare disease therapeutics
  • Clinical stage biotech
  • Ophthalmology contract research

Where Abionyx Pharma is headquartered

Location

Headquarters

HQ city
Balma
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Abionyx Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Contract Research Services (IRIS Pharma): Revenue is generated entirely through IRIS Pharma, a contract research organization (CRO) specializing in ophthalmology. The therapeutic development business (CER-001, ABNX-100) generates no revenue as products remain in clinical development.
  2. Non-dilutive Government Funding: The company secures non-dilutive funding through grants and programs such as France 2030's i-Démo program (€8.7 million secured, €6.5 million remaining) and Bpifrance innovation grants (nearly €1 million for CER-001 ophthalmology development).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Abionyx Pharma product offering

Product offering

Core offering

ABIONYX Pharma is a clinical-stage biotech developing HDL-based biomedicines, principally lead candidate CER-001 (a recombinant apoA-I biomedicine) for LCAT deficiency, sepsis, and ophthalmological indications, along with ABNX-100 as a second pipeline candidate. The company complements its therapeutic development business with its wholly-owned IRIS Pharma subsidiary, a contract research organization that delivers ophthalmology research services and currently generates all of the group's consolidated revenue.

Product overview

ABIONYX Pharma is a new-generation biotech company developing innovative therapies through two main drug candidates: CER-001 (a HDL-based biomedicine for LCAT deficiency, sepsis, and ophthalmology) and ABNX-100. The company also operates through its IRIS Pharma subsidiary, a contract research organization providing ophthalmology research services. The product portfolio centers on HDL vectors used for targeted drug delivery in renal, ophthalmological, and rare diseases where no effective treatment exists.

Differentiator

Problem solved

Functional benefit

Products and services

  • CER-001 CER-001 is ABIONYX Pharma's lead biomedicine drug candidate, based on a recombinant apoA-I HDL vector technology, being developed for the treatment of LCAT (Lecithin-Cholesterol Acyltransferase) deficiency, sepsis, and ophthalmological indications. It is targeted at patients with rare and unmet medical needs, and is being progressed toward a Marketing Authorization Application with the EMA targeted for early 2028.
  • ABNX-100 ABNX-100 is a pipeline drug candidate of ABIONYX Pharma, referenced alongside CER-001 as one of the company's key therapeutic assets for innovative applications leveraging the company's HDL-based bioproduct platform.
  • IRIS Pharma CRO services IRIS Pharma is the wholly-owned contract research organization (CRO) subsidiary of ABIONYX Pharma, specializing in ophthalmology research services for pharmaceutical and biotech companies. It generated all of ABIONYX's consolidated revenue (€4.1 million in FY2025) and had €2.6 million in business secured for FY2026.

Quantifiable outcome

  • Threefold increase in sphingomyelin production yield for CER-001 manufacturing
  • +2 more outcomes

Companies that use Abionyx Pharma

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Abionyx Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Abionyx Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SEBIAcoreStrategic or Co-development Partner · 20 November 2025ABIONYX Pharma and SEBIA announced an exclusive global strategic partnership focused on developing new diagnostic tests for early detection and monitoring of sepsis. The partnership aims to improve sepsis management through combined expertise in lipid biology, clinical studies, and blood sample analysis.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Abionyx Pharma competitors and assessment

Company assessment

Broad incumbents

  • Esperion Therapeutics: Esperion commercializes bempedoic acid (Nexletol/Nexlizet) for LDL cholesterol lowering, addressing lipid-related cardiovascular disease with a similar therapeutic-area focus to ABIONYX. As a small-cap public commercial-stage peer, it offers a comparable go-to-market benchmark for lipid-targeting therapeutics.
  • Recordati Rare Diseases: Recordati's rare diseases division commercializes treatments for rare metabolic and endocrine disorders globally. As an established rare-disease commercial player, it offers a comparable commercialization model and potential partner for CER-001 in LCAT deficiency upon EMA approval.
  • CSL Behring: CSL Behring developed CSL112, an apoA-I infusion therapy very similar in mechanism to CER-001, for cardiovascular indications. It is a major plasma-derived therapeutics incumbent with global commercialization infrastructure, providing both a technology comparable and a precedent (the AEGIS-II Phase 3 outcome) for ABIONYX's HDL-mimetic approach.
  • Sobi (Swedish Orphan Biovitrum): Sobi is a Swedish specialty biopharma focused on rare diseases, with a portfolio spanning hematology, immunology, and specialty therapeutics. It represents a potential commercialization partner or acquisition counterparty for ABIONYX's rare-disease pipeline, particularly for European orphan drug launches.

Direct peers

  • Ionis Pharmaceuticals: Ionis is a leader in antisense oligonucleotide therapies for serious and rare diseases, with multiple approved products (e.g., Waylivra, Tegsedi). Its rare-disease platform focus, lipid targets, and Phase 2-3 pipeline profile closely parallel ABIONYX's specialty biotech model targeting LCAT deficiency and rare renal/ophthalmology indications.

Emerging players

  • Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapies for rare diseases, leveraging a targeted-delivery platform. Its platform-based approach to delivering therapeutics to specific tissues parallels ABIONYX's HDL vector delivery concept, making it a useful comparator for technology-driven rare-disease biotechs.
  • Madrigal Pharmaceuticals: Madrigal developed Rezdiffra, the first FDA-approved therapy for MASH/NASH, addressing a rare metabolic liver disease with no prior approved options. Comparable as a specialty biotech that achieved commercial approval in a previously untreated rare metabolic indication, similar to ABIONYX's LCAT deficiency strategy.
  • Travere Therapeutics: Travere develops therapies for rare kidney diseases (e.g., Filspari for IgA nephropathy), making it a direct comparable to ABIONYX's LCAT deficiency renal focus. It provides a benchmark for small-cap rare renal disease biotechs progressing from clinical to commercial stages.
  • CymaBay Therapeutics: CymaBay developed seladelpar (Livdelzi) for primary biliary cholangitis, a rare autoimmune liver disease. Similar to ABIONYX, it is a small public clinical-to-commercial biotech that targeted a rare disease with no effective existing treatment.
  • Akari Therapeutics: Akari is a clinical-stage biotech developing therapies for rare autoimmune and inflammatory diseases, including nomacopan for conditions with high unmet need. Comparable to ABIONYX as a small-cap public rare-disease biotech with limited headcount and a single-platform therapeutic pipeline.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Abionyx Pharma social profiles

Digital presence

Abionyx Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abionyx Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Abionyx Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Abionyx Pharma funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abionyx Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abionyx Pharma

What does Abionyx Pharma do?

ABIONYX Pharma is a clinical-stage biotech developing HDL-based biomedicines, principally lead candidate CER-001 (a recombinant apoA-I biomedicine) for LCAT deficiency, sepsis, and ophthalmological indications, along with ABNX-100 as a second pipeline candidate. The company complements its therapeutic development business with its wholly-owned IRIS Pharma subsidiary, a contract research organization that delivers ophthalmology research services and currently generates all of the group's consolidated revenue.

Is Abionyx Pharma a public or private company?

Abionyx Pharma is a public company. It is classified as public and is currently operating.

When was Abionyx Pharma founded?

Abionyx Pharma was founded in 2019. It employs 1 to 10 people.

Where is Abionyx Pharma based?

Abionyx Pharma is headquartered in Balma, France, in the Europe region.

How does Abionyx Pharma make money?

Two revenue lines are on record. Contract Research Services (IRIS Pharma) is the primary driver. The others are non-dilutive Government Funding.

Who are Abionyx Pharma's main competitors?

Broad incumbents on record are Esperion Therapeutics, Recordati Rare Diseases, CSL Behring and Sobi (Swedish Orphan Biovitrum). Ionis Pharmaceuticals is listed as a direct peer. Emerging players are Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, Travere Therapeutics, CymaBay Therapeutics and Akari Therapeutics.

Does Abionyx Pharma have an API?

No public API is recorded for Abionyx Pharma.

What industry is Abionyx Pharma in?

Abionyx Pharma's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRLogWhen Is a Biotech Milestone a Real CDMO Opportunity?CDMOs can qualify biotech milestones before an RFP by assessing work packages, existing suppliers, technical fit, and timing. The article advises separate evaluation of each work package, citing ABIONYX and Vedanta as examples where disclosed suppliers may reduce priority for new suppliers.PRLogWhen Is a Biotech Milestone a Real CDMO Opportunity?[CDMOs can qualify biotech milestones before an RFP by assessing work packages, existing suppliers, technical fit, and timing. The article advises separate judgments for each work package, citing ABIONYX and Vedanta as examples where disclosed suppliers may reduce priority.Business Wire BlogABIONYX Pharma Signs a Strategic Partnership with Lille University Hospital—Burn Treatment Center and Intensive Care Unit—to Explore the Potential of CER-001 in Severe Burn Patients at High Risk for SABIONYX Pharma signed a strategic partnership with Lille University Hospital to study CER-001 in severe burn and ICU patients at high sepsis risk. The collaboration will examine apoA-I and endotoxin dynamics to refine CER-001's host-restorative approach. Data may support expanding CER-001 beyond sepsis to broader immuno-inflammatory dysregulation.YahooABIONYX Pharma Finalizes the Structuring of Its CER-001 Bioproduction Chain Through a Strategic Partnership with AXPLORA, Marking a Major Milestone Toward Its Potential CommercializationABIONYX Pharma finalized its CER-001 production chain by partnering with AXPLORA for purification of recombinant human apoA-I at its Pompey site. The partnership complements agreements with TEXCELL and OLON, supporting development for LCAT Deficiency and a Phase 2b sepsis trial. The company aims to secure regulatory approval for LCAT Deficiency.Business Wire BlogABIONYX Pharma Finalizes the Structuring of Its CER-001 Bioproduction Chain Through a Strategic Partnership with AXPLORA, Marking a Major Milestone Toward Its Potential CommercializationABIONYX Pharma finalized its CER-001 bioproduction chain by partnering with AXPLORA for purification of recombinant human apoA-I at its Pompey site. The partnership completes the manufacturing network with TEXCELL and OLON, supporting regulatory approval for LCAT Deficiency and a Phase 2b trial for Sepsis.Business Wire BlogABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial SupplyABIONYX Pharma and OLON announced a strategic manufacturing partnership to produce CER-001, a biologic for LCAT deficiency and sepsis. The collaboration will initially make two validation batches and establish industrial capabilities for future commercial supply. The partnership aims to support CER-001's regulatory pathway and potential market entry.Business Wire BlogABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing AgreementABIONYX Pharma settled EUR 1.75 million in bond amortization, with EUR 0.52 million paid via 331,299 new shares to Fenja Capital. The cash portion of EUR 1.23 million will be paid by October 2, 2026, leaving outstanding principal at EUR 8.25 million. The company's cash runway remains unchanged into Q4 2028.YahooABIONYX Pharma: Half Year Results 2026ABIONYX Pharma reported H1 2026 revenue of €1.9M, all from IRIS Pharma's CRO activities, with no revenue from its sepsis and LCAT deficiency programs. The company posted a net loss of €4.8M, down from €2.3M in H1 2025, and held €26.9M in cash as of June 30, 2026.Investing.comWhy is Abionyx Pharma stock climbing today? By Investing.comStifel initiated coverage of Abionyx Pharma with a buy rating and €8.50 price target, lifting the stock 6.8% to €1.818. The company's sepsis drug CER-001 and LCAT deficiency treatment are in development, with a Phase 2b trial expected in Q4. The half-year 2026 earnings release is due September 24, 2026.Business Wire BlogABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of BiologicsABIONYX Pharma partnered with TEXCELL (ABL Diagnostics) to conduct viral safety and clearance studies for its biologic CER-001. The collaboration supports validation batches for regulatory compliance, aiming to advance industrialization and prepare for a future market launch for LCAT deficiency.